You are here

FDA Approves New Labeling for Raltegravir (Isentress) for Untreated Adults With HIV-1

Updated label includes phase III study data (July 1)

The FDA has approved new labeling for raltegravir (Isentress, Merck) — an integrase inhibitor for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients as part of combination HIV therapy.

The updated prescribing information now includes 240-week results from the phase III STARTMRK trial in treatment-naïve adult patients with HIV-1 infection. In this study, a regimen containing raltegravir was non-inferior to a regimen containing efavirenz at reducing the HIV-1 viral load to undetectable levels (less than 50 copies/mL) at 240 weeks.

Long-term viral suppression (HIV-1 RNA less than 50 copies/mL) was observed in 66% of patients on the raltegravir-containing regimen compared with 60% of those on the efavirenz-containing regimen.

In addition, the raltegravir regimen demonstrated a greater immunologic response than did the efavirenz regimen at 240 weeks. Patients on the regimen containing raltegravir had a mean baseline CD4 cell count of 219 cells/mm3 compared with 217 cells/mm3 for patients on the regimen containing efavirenz. From study entry to week 240, patients on the regimen containing raltegravir had a mean baseline increase in the CD4 cell count of 295 cells/mm3 versus 236 cells/mm3 for patients on the regimen containing efavirenz.

Through 240 weeks of treatment, a low incidence of drug-related adverse reactions of moderate-to-severe intensity occurred in patients treated with raltegravir. These adverse drug reactions, compared with efavirenz, were insomnia (4% in both arms), headache (4% vs. 5%), nausea (3% vs. 4%), fatigue (2% vs. 3%), and dizziness (2% vs. 6%).

Source: Merck; July 2, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time